Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

MAMO sees a 30.7% increase in non-GAAP operating income in Q3 2024. Healthcare segment revenues increase 11.5%, driving overall growth amid strategic shifts.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ETCompany ParticipantsEli Kammerman - VP of Business ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

The global non-invasive respiratory monitoring market is poised for substantial growth, projected to increase from an estimated valuation of USD 8.4 Billion in 2023 to USD 15.0 Billion by 2033, at a ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

A variety of medical device innovations and diagnostics have been named by Time as some of the best inventions of 2024.